PanOncology Trials

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Childhood cancers2 trials
• Gastric and oesophageal cancer2 trials
• Metastatic breast cancer2 trials
• Ovarian cancer2 trials
• Cervical cancer1 trial
• Endometrial cancer1 trial
• Head and neck cancer1 trial
• Liver and biliary tract cancer1 trial
• Lung cancer1 trial
• Multiple myeloma1 trial
• Pancreatic cancer1 trial
• Prostate cancer1 trial

Phase

• Phase 24 trials
• Phase 33 trials
• Phase 11 trial
• Phase 1/21 trial

Status

• Recruiting6 trials
• Active, not recruiting3 trials

Lead sponsor

• Hoffmann-La Roche4 trials
• Astellas Pharma Global Development, Inc.2 trials
• American Society of Clinical Oncology1 trial
• Incyte Corporation1 trial
• Terremoto Biosciences Inc.1 trial

Running trials

• Recruiting

  A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07023627· Phase 2· Incyte Corporation· Source

• Recruiting

  A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  NCT07109726· Phase 1/2· Terremoto Biosciences Inc.· Source

  Contact: Study Coordinator

• Recruiting

  A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

  NCT07005154· Phase 2· Astellas Pharma Global Development, Inc.· Source

  Contact: Astellas Pharma Global Development, Inc.

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

  NCT06065748· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

  NCT05904886· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

  NCT05365581· Phase 1· Astellas Pharma Global Development, Inc.· Source

  Contact: Astellas Pharma Global Development, Inc.

• Active, not recruiting

  Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

  NCT04589845· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  NCT02693535· Phase 2· American Society of Clinical Oncology· Source

  Contact: Natalia Ortiz

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gastric and oesophageal cancer2 recruiting
• Ovarian cancer2 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• Endometrial cancer1 recruiting
• Head and neck cancer1 recruiting
• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting